Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings call transcript of the call held on October 30, 202303-11-2023
03-11-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Unaudited Financial Results for quarter and half year ended September 30, 202331-10-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC to Mr. Dinesh P Jain31-10-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings Call - Audio recording30-10-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Mr. Ramaraju PVS as the Chief Operating Officer of the Company effective March 1, 202430-10-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Cessation
Resignation of Mr. Christoph Funke, Chief Operating Officer of the Company effective February 29, 202430-10-2023
Strides Pharma Science Q2 loss at Rs 149 crore
The drug firm had reported a net profit of Rs 19 crore for the year-ago period.30-10-2023
Strides Pharma Science Ltd - 532531 - Statement Of Deviation & Variation For Quarter Ended September 30, 2023
Statement of Deviation & Variation for quarter ended September 30, 202330-10-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment
Allotment of Shares30-10-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports Strong Q2FY24 Performance - Revenues at Rs. 10,264m and EBITDA at Rs. 1,801m.30-10-2023